Streetbeat News

Stock Prices

FIGS

MOTS

TTD

Figs shares rose premarket due to investor Ron Baron discussing the stock on CNBC. The Trade Desk shares fell after issuing Q4 revenue guidance below estimates. Motus GI announced the first upper GI patient procedure for FDA cleared Pure-Vu® EVS Gastro, causing a significant rise in its shares.

Portfolio Pulse from ryanfaloona@benzinga.com

November 10, 2023 | 1:42 pm

TWOU

2U Inc. reported mixed Q3 financial results and reduced its 2023 revenue guidance, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:42 pm

FBIO

Fortress Biotech has announced the pricing of a $10 million public offering, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:41 pm

MOTS

Motus GI announced that the Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance, leading to a rise in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:40 pm

SHCO

Soho House & Co reported its Q3 financial results and issued guidance, following which its shares traded lower.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:39 pm

TSLA

Tesla, Inc. is reportedly launching its first direct operation in South America, specifically in Chile. The company has registered its name and started hiring for various roles. This move marks Tesla's first direct commercial venture in South America. Meanwhile, TSLA shares are trading lower by 0.63% to $208.66 premarket on the last check Friday.

Portfolio Pulse from Nabaparna Bhattacharya

November 10, 2023 | 1:38 pm

NVTS

Navitas Semiconductor reported its Q3 financial results and issued guidance, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:38 pm

VZIO

VIZIO has reported its Q3 financial results, leading to an increase in its share prices.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:37 pm

VALN

The FDA has approved Valneva SE's (NASDAQ:VALN) single-dose Chikungunya vaccine for individuals aged 18 and above. The company plans to start selling the vaccine, Ixchiq, in the U.S. early next year. This makes Ixchiq the world's first licensed Chikungunya vaccine. Valneva's shares are up 6.04% premarket on the news.

Portfolio Pulse from Vandana Singh

November 10, 2023 | 1:37 pm

INDI

Indie Semiconductor reported better-than-expected Q3 sales results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:37 pm